ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts 登録してリアルタイムのチャート、分析ツール、価格を入手してください。
Silexion Therapeutics Corporation

Silexion Therapeutics Corporation (SLXN)

1.31
0.05
(3.97%)
終了 2月11日 6:00AM
1.43
0.12
( 9.16% )
プレマーケット: 8:13PM

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

主要統計と詳細

通貨
1.43
買値
1.43
売値
1.44
出来高
377,247
0.00 日の範囲 0.00
0.575 52 週間の範囲 36.36
前日終値
1.31
始値
-
最終取引時間
20:13:53
平均取引量 (3 か月)
16,167,510
財務取引量
-
VWAP
-

SLXN 最新ニュース

Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds

Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for...

PESG Report: Silexion Therapeutics’ Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market

Silexion Therapeutics reported 50% Tumor Reduction in Breakthrough Preclinical Systemic Administration Data; Maxim Group Analyst recently gave the company a Strong Buy Rating and a $9 Price...

Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models

Cayman Islands, January 28, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for...

PESG Market Update: Silexion Therapeutics’ SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments

KRAS, one of the most mutated oncogenes across cancers, drives aggressive and treatment-resistant tumors. Silexion’s latest data highlights SIL-204’s ability to enhance first-line therapies...

Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering

Cayman Islands, January 15, 2025 -- Silexion Therapeutics Corp (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for...

Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies

Cayman Islands, January 15, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven...

Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium

Cayman Islands, January 13, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven...

PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises

Silexion Therapeutics (NASDAQ: SLXN) is advancing precision oncology with a focus on KRAS-driven cancers, among the most challenging targets in oncology. In collaboration with Evonik, Silexion...

Silexion Therapeutics collaborates with Evonik on advanced siRNA Formulation Development

Cayman Islands, December 17, 2024 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven...

Silexion Is Addressing the MOST COMMON Human Cancer Gene Mutation With RNAi; Recent M&As in the Field Were for Tens of Billions - $SLXN

December 11, 2024 -- InvestorsHub NewsWire -- via PESG Research -- The field of precision oncology has witnessed groundbreaking advancements in recent years, and Silexion Therapeutics (NASDAQ:...

期間 †前日比前日比 %始値高値安値平均出来高VWAP
1-0.07-4.666666666671.51.73991.245384791.36729406CS
4-0.43-23.11827956991.863.450.575352371832.29838066CS
12-0.600409-29.57084016082.0304094.230.575161675102.47698428CS
26-34.57-96.02777777783636.360.57587726533.25356707CS
52-34.57-96.02777777783636.360.57587726533.25356707CS
156-34.57-96.02777777783636.360.57587726533.25356707CS
260-34.57-96.02777777783636.360.57587726533.25356707CS

SLXN - Frequently Asked Questions (FAQ)

What is the current Silexion Therapeutics share price?
The current share price of Silexion Therapeutics is US$ 1.43
What is the 1 year trading range for Silexion Therapeutics share price?
Silexion Therapeutics has traded in the range of US$ 0.575 to US$ 36.36 during the past year

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
OCEAOcean Biomedical Inc
US$ 0.2387
(61.28%)
75.42M
NOEMCO2 Energy Transition Corporation
US$ 15.76
(59.68%)
4
BBGIBeasley Broadcast Group Inc
US$ 12.48
(59.18%)
4
VSTEVast Renewable Ltd
US$ 1.085
(57.25%)
15.62M
BSBKBogota Financial Corporation
US$ 12.29
(55.18%)
9
AIRJAirJoule Technologies Corporation
US$ 5.21
(-41.00%)
1
PRAAPRA Group Inc
US$ 14.01
(-39.69%)
7
FLNCFluence Energy Inc
US$ 8.41
(-35.65%)
367.15k
SLNGStabilis Solutions Inc
US$ 5.12
(-33.16%)
6
PEBKPeoples Bancorp of North Carolina Inc
US$ 21.01
(-29.97%)
6
CYNCYNGN Inc
US$ 0.277
(49.97%)
125.06M
OCEAOcean Biomedical Inc
US$ 0.2387
(61.28%)
75.42M
BHATBlue Hat Interactive Entertainment Technology
US$ 0.087
(26.09%)
32.53M
CLEUChina Liberal Education Holdings Ltd
US$ 0.1323
(21.94%)
27.16M
VSTEVast Renewable Ltd
US$ 1.085
(57.25%)
15.62M

SLXN Discussion

投稿を表示

最近閲覧した銘柄

Delayed Upgrade Clock